Sugi Predict

Sugi Predict / Targets / IL15

IL15

Interleukin-15 · P40933 · IL15 on Sugi Atlas →

141 patent compounds predicted against IL15, 95 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17293539 SCHEMBL17293539 1.00 20/20
SCHEMBL17293612 SCHEMBL17293612 1.00 20/20
SCHEMBL17293788 SCHEMBL17293788 1.00 20/20
SCHEMBL17293792 SCHEMBL17293792 1.00 20/20
SCHEMBL17293797 SCHEMBL17293797 1.00 20/20
SCHEMBL17293815 SCHEMBL17293815 1.00 20/20
SCHEMBL17293831 SCHEMBL17293831 1.00 20/20
SCHEMBL17293839 SCHEMBL17293839 1.00 20/20
SCHEMBL31158149 SCHEMBL31158149 1.00 20/20
SCHEMBL31158150 SCHEMBL31158150 1.00 20/20
SCHEMBL17302311 SCHEMBL17302311 0.86 20/20
SCHEMBL17293856 SCHEMBL17293856 0.82 20/20
SCHEMBL17293749 SCHEMBL17293749 0.74 20/20
SCHEMBL17293791 SCHEMBL17293791 0.74 20/20
SCHEMBL17293880 SCHEMBL17293880 0.68 20/20
SCHEMBL17293829 SCHEMBL17293829 0.63 20/20
SCHEMBL17293542 SCHEMBL17293542 1.00 19/20
SCHEMBL17293576 SCHEMBL17293576 0.82 18/20
SCHEMBL17293591 SCHEMBL17293591 0.70 18/20
SCHEMBL17293745 SCHEMBL17293745 0.70 18/20

Clinical trials — most relevant to IL15 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma PHASE4UNKNOWN
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma PHASE1/PHASE2COMPLETED
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients PHASE2COMPLETED
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction PHASE2RECRUITING
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma PHASE1/PHASE2UNKNOWN
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia PHASE2RECRUITING
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels PHASE2NOT_YET_RECRUITING
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma PHASE2COMPLETED
Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia PHASE1/PHASE2COMPLETED
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma PHASE2COMPLETED
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. PHASE2WITHDRAWN
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma PHASE1/PHASE2RECRUITING
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer PHASE1COMPLETED
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers PHASE1COMPLETED
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome PHASE1COMPLETED
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer PHASE1COMPLETED
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors PHASE1COMPLETED
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer PHASE1COMPLETED
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) PHASE1COMPLETED
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies PHASE1COMPLETED
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) PHASE1COMPLETED
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors PHASE1UNKNOWN
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies PHASE1COMPLETED
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis PHASE1COMPLETED
Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions PHASE1NOT_YET_RECRUITING
IL-15 Enhanced NK Cell Therapy for Solid Tumors EARLY_PHASE1NOT_YET_RECRUITING
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors nanRECRUITING
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases. nanCOMPLETED
Novel Targetable BIOmarkers in ANorexia NervosA nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a IL15 binder may also engage these)

ProteinNameSimilarity
B3F0J0 — 1.000 B3F0J0 →
Q9XSJ6 — 1.000 Q9XSJ6 →
Q4GZL1 — 1.000 Q4GZL1 →
Q28028 — 1.000 Q28028 →
P48346 — 1.000 P48346 →
Q75SZ9 — 1.000 Q75SZ9 →
P97604 — 1.000 P97604 →
B0ZE70 — 1.000 B0ZE70 →
P40221 — 1.000 P40221 →
Q5WQV8 — 1.000 Q5WQV8 →
O97687 — 1.000 O97687 →
Q4U0U2 — 0.999 Q4U0U2 →
P48092 — 0.998 P48092 →
Q6EBC2 — 0.998 Q6EBC2 →
Q95253 — 0.998 Q95253 →
Q9XT91 — 0.997 Q9XT91 →
Q3Y5G8 — 0.996 Q3Y5G8 →
Q28132 — 0.996 Q28132 →
IL2 Interleukin-2 0.994 landscape →
Q6EAL8 — 0.994 Q6EAL8 →
P52173 — 0.994 P52173 →
Q9XSW9 — 0.993 Q9XSW9 →
Q08125 — 0.993 Q08125 →
P20096 — 0.992 P20096 →
P51744 — 0.992 P51744 →
P51748 — 0.992 P51748 →
P42202 — 0.992 P42202 →
Q588F9 — 0.992 Q588F9 →
Q95M19 — 0.991 Q95M19 →
O54831 — 0.991 O54831 →